Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07361484CT.gov Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | — | Not Yet Recruiting | — | — | — |
NCT07524257CT.gov Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07528274CT.gov Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure | — | Recruiting | — | — | — |
NCT07609251CT.gov A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | — | Not Yet Recruiting | — | — | — |
NCT07566052CT.gov A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | — | Recruiting | — | — | — |
NCT07464327CT.gov A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | — | Not Yet Recruiting | — | — | — |
NCT07416994CT.gov Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06951646CT.gov ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) | — | Recruiting | — | — | — |
NCT07442565CT.gov SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ | — | Not Yet Recruiting | — | — | — |
NCT07472647CT.gov SYS6090 Combination Therapy in Advanced Lung Cancer | — | Not Yet Recruiting | — | — | — |
Show 302 more trialsShow fewer
NCT07306624CT.gov Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07242274CT.gov Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07358806CT.gov Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06908993CT.gov Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | — | Recruiting | — | — | — |
NCT06908304CT.gov A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | — | Recruiting | — | — | — |
NCT07330050CT.gov WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | — | Recruiting | — | — | — |
NCT07001618CT.gov Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07291037CT.gov Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT07246863CT.gov Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | — | Recruiting | — | — | — |
NCT06745908CT.gov Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In | — | Recruiting | — | — | — |
NCT06484491CT.gov IMPT Dose Escalation for NSCLC (HyDose) | — | Recruiting | — | — | — |
NCT07070440CT.gov DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | — | Recruiting | — | — | — |
NCT06924606CT.gov Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy | — | Recruiting | — | — | — |
NCT06928389CT.gov Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06616584CT.gov Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | — | Recruiting | — | — | — |
NCT06943820CT.gov AK129 Combination Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06929936CT.gov Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC | — | Recruiting | — | — | — |
NCT06881784CT.gov Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | — | Recruiting | — | — | — |
NCT06879717CT.gov A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | — | Active Not Recruiting | — | — | — |
NCT06868732CT.gov Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | — | Recruiting | — | — | — |
NCT06841055CT.gov Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment | — | Recruiting | — | — | — |
NCT06775483CT.gov Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06472245CT.gov Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | — | Recruiting | — | — | — |
NCT06635824CT.gov Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | — | Active Not Recruiting | — | — | — |
NCT06463665CT.gov Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | — | Recruiting | — | — | — |
NCT06532032CT.gov A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT06525350CT.gov A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06382129CT.gov A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | — | Active Not Recruiting | — | — | — |
NCT06228326CT.gov A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | — | Recruiting | — | — | — |
NCT06300177CT.gov D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | — | Recruiting | — | — | — |
NCT06012435CT.gov A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06266299CT.gov A Study of KK2269 in Adult Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT06182800CT.gov Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy | — | Unknown | — | — | — |
NCT06074588CT.gov Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | — | Active Not Recruiting | — | — | — |
NCT06029127CT.gov A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05919537CT.gov Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | — | Active Not Recruiting | — | — | — |
NCT05777278CT.gov Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | — | Recruiting | — | — | — |
NCT05904379CT.gov AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05910034CT.gov Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT05671510CT.gov ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | — | Recruiting | — | — | — |
NCT05863325CT.gov A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT05673590CT.gov Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05639751CT.gov PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | — | Completed | — | — | — |
NCT06141226CT.gov Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05616624CT.gov ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | — | Active Not Recruiting | — | — | — |
NCT05633667CT.gov Study of Novel Treatment Combinations in Patients With Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05800587CT.gov Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | — | Recruiting | — | — | — |
NCT05676931CT.gov Study With Various Immunotherapy Treatments in Participants With Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05816499CT.gov Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05599789CT.gov Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | — | Unknown | — | — | — |
NCT05543629CT.gov A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05878028CT.gov L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC | — | Unknown | — | — | — |
NCT05450692CT.gov A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT05431270CT.gov Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | — | Recruiting | — | — | — |
NCT05383482CT.gov Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | — | Completed | — | — | — |
NCT05142189CT.gov Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05132075CT.gov Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05215067CT.gov A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05378763CT.gov A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | — | Suspended | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05062980CT.gov Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | — | Terminated | — | — | — |
NCT04928846CT.gov A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT04878107CT.gov SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy | — | Unknown | — | — | — |
NCT05096663CT.gov Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT05106335CT.gov A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | — | Terminated | — | — | — |
NCT05020457CT.gov SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | — | Active Not Recruiting | — | — | — |
NCT04430933CT.gov A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | — | Withdrawn | — | — | — |
NCT05089734CT.gov Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05084859CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05001724CT.gov KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | — | Terminated | — | — | — |
NCT04880863CT.gov NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC | — | Completed | — | — | — |
NCT04884282CT.gov Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) | — | Active Not Recruiting | — | — | — |
NCT05116891CT.gov A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05094804CT.gov A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | — | Unknown | — | — | — |
NCT04846634CT.gov Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) | — | Not Yet Recruiting | — | — | — |
NCT04921358CT.gov Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT06542731CT.gov An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04895709CT.gov A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04863248CT.gov Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | — | Terminated | — | — | — |
NCT04725188CT.gov Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | — | Completed | — | — | — |
NCT04151563CT.gov A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | — | Withdrawn | — | — | — |
NCT04721015CT.gov Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04685135CT.gov Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04364620CT.gov AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | — | Completed | — | — | — |
NCT04736823CT.gov A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | — | Active Not Recruiting | — | — | — |
NCT04656652CT.gov Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | — | Active Not Recruiting | — | — | — |
NCT04655976CT.gov Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT04619563CT.gov A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT04396535CT.gov Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04619537CT.gov A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04471428CT.gov Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | — | Completed | — | — | — |
NCT04427072CT.gov Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | — | Terminated | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04447118CT.gov Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy | — | Completed | — | — | — |
NCT04340882CT.gov Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade | — | Active Not Recruiting | — | — | — |
NCT04303780CT.gov Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | — | Active Not Recruiting | — | — | — |
NCT04367311CT.gov Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | — | Active Not Recruiting | — | — | — |
NCT03990077CT.gov Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | — | Terminated | — | — | — |
NCT04154956CT.gov SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients | — | Terminated | — | — | — |
NCT04256707CT.gov Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | — | Completed | — | — | — |
NCT04165031CT.gov A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | — | Terminated | — | — | — |
NCT03833440CT.gov Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | — | Unknown | — | — | — |
NCT03906071CT.gov Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03976375CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | — | Completed | — | — | — |
NCT03971474CT.gov Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | — | Completed | — | — | — |
NCT03845270CT.gov Her2-positive Lung Cancer Treated With Dedicated Drug | — | Completed | — | — | — |
NCT03840915CT.gov M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03863483CT.gov A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy. | — | Unknown | — | — | — |
NCT03830411CT.gov A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy | — | Unknown | — | — | — |
NCT03799601CT.gov Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC | — | Unknown | — | — | — |
NCT03611738CT.gov Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT03626545CT.gov Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | — | Terminated | — | — | — |
NCT03798743CT.gov Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study | — | Completed | — | — | — |
NCT03647488CT.gov Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03726736CT.gov Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC | — | Unknown | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03750916CT.gov Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03735264CT.gov Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） | — | Unknown | — | — | — |
NCT03732001CT.gov A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC | — | Unknown | — | — | — |
NCT03624309CT.gov Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03654027CT.gov Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT03646968CT.gov Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study | — | Unknown | — | — | — |
NCT03566576CT.gov Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel | — | Unknown | — | — | — |
NCT03370159CT.gov CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03574649CT.gov QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03095612CT.gov Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03228186CT.gov Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03407300CT.gov A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients | — | Unknown | — | — | — |
NCT03337698CT.gov A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | — | Terminated | — | — | — |
NCT03358875CT.gov Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03178552CT.gov A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03288870CT.gov Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) | — | Unknown | — | — | — |
NCT03150875CT.gov A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | — | Completed | — | — | — |
NCT03256721CT.gov Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | — | Terminated | — | — | — |
NCT03158129CT.gov Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03137771CT.gov Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02998528CT.gov A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03416231CT.gov Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02831491CT.gov A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT02922777CT.gov Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | — | Completed | — | — | — |
NCT03269162CT.gov Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection | — | Unknown | — | — | — |
NCT02864394CT.gov Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | — | Completed | — | — | — |
NCT02884479CT.gov An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | — | Unknown | — | — | — |
NCT03394105CT.gov Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer | — | Completed | — | — | — |
NCT02642042CT.gov Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02813785CT.gov A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy | — | Completed | — | — | — |
NCT02740985CT.gov A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT02766140CT.gov SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02451865CT.gov Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT02574598CT.gov MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT02780778CT.gov Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02654587CT.gov OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure | — | Terminated | — | — | — |
NCT02460367CT.gov Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02504489CT.gov Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC | — | Completed | — | — | — |
NCT02574078CT.gov A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02326285CT.gov Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | — | Terminated | — | — | — |
NCT02486718CT.gov Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | — | Active Not Recruiting | — | — | — |
NCT02643407CT.gov Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer | — | Unknown | — | — | — |
NCT02495896CT.gov Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02450539CT.gov A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02522910CT.gov An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT02577341CT.gov Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | — | Completed | — | — | — |
NCT02393209CT.gov Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02450656CT.gov Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02664935CT.gov National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02395172CT.gov Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | — | Completed | — | — | — |
NCT02346370CT.gov A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC | — | Terminated | — | — | — |
NCT02322281CT.gov TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | — | Terminated | — | — | — |
NCT02387216CT.gov A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | — | Terminated | — | — | — |
NCT02364362CT.gov A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02972216CT.gov Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy | — | Completed | — | — | — |
NCT02257619CT.gov Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02179671CT.gov Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT02117024CT.gov A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02191059CT.gov Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer | — | Unknown | — | — | — |
NCT02134990CT.gov Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02008227CT.gov A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy | — | Completed | — | — | — |
NCT01824901CT.gov Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02031601CT.gov Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer | — | Unknown | — | — | — |
NCT01999673CT.gov Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01938456CT.gov Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT02001168CT.gov Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB | — | Unknown | — | — | — |
NCT01933932CT.gov Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC | — | Active Not Recruiting | — | — | — |
NCT01951157CT.gov A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | — | Completed | — | — | — |
NCT01905657CT.gov Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | — | Completed | — | — | — |
NCT01903993CT.gov A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | — | Completed | — | — | — |
NCT01828112CT.gov LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | — | Completed | — | — | — |
NCT01741155CT.gov Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT01935947CT.gov Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01798485CT.gov A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | — | Terminated | — | — | — |
NCT01774578CT.gov Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01750281CT.gov Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. | — | Completed | — | — | — |
NCT01708993CT.gov Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | — | Completed | — | — | — |
NCT01703091CT.gov A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01755923CT.gov Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC | — | Unknown | — | — | — |
NCT01646125CT.gov An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | — | Terminated | — | — | — |
NCT01630733CT.gov A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01714037CT.gov A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] | — | Terminated | — | — | — |
NCT01671332CT.gov Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01454934CT.gov A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01561456CT.gov Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | — | Completed | — | — | — |
NCT01362296CT.gov An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01395758CT.gov Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01282151CT.gov TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer | — | Terminated | — | — | — |
NCT01350817CT.gov Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01348126CT.gov Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01362400CT.gov A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01577654CT.gov Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01424709CT.gov Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01168973CT.gov A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | — | Completed | — | — | — |
NCT01204697CT.gov A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | — | Completed | — | — | — |
NCT01204099CT.gov Study of PX-866 and Docetaxel in Solid Tumors | — | Completed | — | — | — |
NCT00697060CT.gov A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT01356368CT.gov Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01107444CT.gov Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00966914CT.gov Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | — | Completed | — | — | — |
NCT00995761CT.gov Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00932893CT.gov An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | — | Completed | — | — | — |
NCT00983047CT.gov Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer | — | Terminated | — | — | — |
NCT00975767CT.gov A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01209520CT.gov Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | — | Completed | — | — | — |
NCT01192230CT.gov Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT00890825CT.gov AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | — | Completed | — | — | — |
NCT00887315CT.gov The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00908336CT.gov Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen | — | Unknown | — | — | — |
NCT01356303CT.gov Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer | — | Suspended | — | — | — |
NCT00862134CT.gov Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00835471CT.gov 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01019798CT.gov Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00738387CT.gov A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00783471CT.gov Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00771953CT.gov 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00813332CT.gov Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT00771563CT.gov Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES) | — | Completed | — | — | — |
NCT00687297CT.gov Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01442909CT.gov Pemetrexed Followed by Docetaxel or in Reverse Sequence | — | Completed | — | — | — |
NCT00705549CT.gov Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | — | Terminated | — | — | — |
NCT00617656CT.gov Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma | — | Terminated | — | — | — |
NCT00801801CT.gov Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC | — | Terminated | — | — | — |
NCT02889666CT.gov A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT00621049CT.gov Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC | — | Completed | — | — | — |
NCT00647426CT.gov Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | — | Completed | — | — | — |
NCT00536107CT.gov Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00906061CT.gov Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients | — | Unknown | — | — | — |
NCT00905983CT.gov Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients | — | Unknown | — | — | — |
NCT00544960CT.gov A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00532155CT.gov A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT00478699CT.gov Randomized Customized Adjuvant Chemotherapy (GECP-SCAT) | — | Completed | — | — | — |
NCT00386555CT.gov A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. | — | Withdrawn | — | — | — |
NCT00565227CT.gov Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | — | Terminated | — | — | — |
NCT00354562CT.gov A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00406302CT.gov Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00379717CT.gov Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT00312377CT.gov ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00418704CT.gov Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00556322CT.gov A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00308750CT.gov First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00243204CT.gov Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | — | Terminated | — | — | — |
NCT00434668CT.gov Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00132379CT.gov ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00326378CT.gov Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00327288CT.gov Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | — | Completed | — | — | — |
NCT00478049CT.gov Iressa as Second Line Therapy in Advanced NSCLC-Asia | — | Completed | — | — | — |
NCT00130780CT.gov Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC | — | Completed | — | — | — |
NCT00118183CT.gov Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00232206CT.gov Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00271323CT.gov Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients | — | Terminated | — | — | — |
NCT00424853CT.gov ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00145418CT.gov Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00172380CT.gov Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III | — | Completed | — | — | — |
NCT01083589CT.gov Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00095199CT.gov Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00112294CT.gov Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02127372CT.gov Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | — | Terminated | — | — | — |
NCT00260026CT.gov Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00198393CT.gov Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | — | Completed | — | — | — |
NCT00582634CT.gov Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00088933CT.gov Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00086268CT.gov Non-small Cell Lung Cancer Study US75 (Z-PACT) | — | Completed | — | — | — |
NCT00076388CT.gov Iressa Versus Docetaxel (Taxotere) | — | Completed | — | — | — |
NCT00622349CT.gov Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00097851CT.gov Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00082472CT.gov Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) | — | Unknown | — | — | — |
NCT00074022CT.gov GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | — | Completed | — | — | — |
NCT00682383CT.gov Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00073385CT.gov Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00065182CT.gov Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00231465CT.gov Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00066768CT.gov Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00066885CT.gov Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00047801CT.gov Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00047840CT.gov This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | — | Completed | — | — | — |
NCT00048087CT.gov Iressa/Docetaxel in Non-Small-Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00425191CT.gov Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer. | — | Completed | — | — | — |
NCT01652820CT.gov Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00020709CT.gov Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00051571CT.gov Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Genfleet Therapeutics (Shanghai) Inc. | Approved | BB · 67 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →